These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 35086838)
1. Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging. Chassagnon G; Campredon A; Vakalopoulou M; Burgel PR Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 35086838 [No Abstract] [Full Text] [Related]
2. Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis. Zhang B; Zhang S Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 35086826 [No Abstract] [Full Text] [Related]
3. Combination Therapy with Lumacaftor-Ivacaftor in Cystic Fibrosis. Keeping It Real. Sala MA; Jain M Am J Respir Crit Care Med; 2020 Jan; 201(2):133-134. PubMed ID: 31639314 [No Abstract] [Full Text] [Related]
4. Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR. Egan ME Am J Respir Crit Care Med; 2017 Apr; 195(7):849-850. PubMed ID: 28362199 [No Abstract] [Full Text] [Related]
5. A cocktail drug therapy for patients with cystic fibrosis? Chen JH J Cyst Fibros; 2014 Sep; 13(5):489-90. PubMed ID: 25088968 [No Abstract] [Full Text] [Related]
6. Another Beginning for Cystic Fibrosis Therapy. Davis PB N Engl J Med; 2015 Jul; 373(3):274-6. PubMed ID: 25981385 [No Abstract] [Full Text] [Related]
8. A new chapter in therapy for cystic fibrosis. Bilton D Lancet Respir Med; 2015 Jul; 3(7):e20. PubMed ID: 26117158 [No Abstract] [Full Text] [Related]
9. Can lumacaftor-ivacaftor reverse glucose-tolerance abnormalities in cystic fibrosis? Kessler L J Cyst Fibros; 2020 Jul; 19(4):666. PubMed ID: 32387043 [No Abstract] [Full Text] [Related]
10. The study of CFTR modulators in the very young. Flume PA Lancet Respir Med; 2019 Apr; 7(4):287-289. PubMed ID: 30686766 [No Abstract] [Full Text] [Related]
11. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Rehman A; Baloch NU; Janahi IA N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035 [No Abstract] [Full Text] [Related]
12. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Wainwright CE; Elborn JS; Ramsey BW N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034 [No Abstract] [Full Text] [Related]
15. Orkambi in patients with severe disease - Bumps in the road to CFTR modulation. Horsley A; Barry P J Cyst Fibros; 2017 May; 16(3):311-312. PubMed ID: 28433526 [No Abstract] [Full Text] [Related]
16. Biomarkers: Their Role in CFTR Modulator Therapies from Early Development to the Clinic. Bell SC; Wood ME Am J Respir Crit Care Med; 2018 Jun; 197(11):1375-1376. PubMed ID: 29406823 [No Abstract] [Full Text] [Related]
17. The PROSPECT Is Bright for CFTR Modulators. Montemayor K; Lechtzin N Ann Am Thorac Soc; 2021 Jan; 18(1):32-33. PubMed ID: 33385230 [No Abstract] [Full Text] [Related]
18. Restoration of exocrine pancreatic function in child with lumacaftor/ivacaftor therapy in cystic fibrosis. Crowley J; Croinin K; Mullane D; Chróinín MN J Cyst Fibros; 2022 Mar; 21(2):264. PubMed ID: 34511391 [No Abstract] [Full Text] [Related]
19. Cystic fibrosis drug is not cost effective, says NICE. Gulland A BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384 [No Abstract] [Full Text] [Related]
20. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877 [No Abstract] [Full Text] [Related] [Next] [New Search]